Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor

Neuropharmacology

Volumn 77, Issue , 2014, Pages 334-341

  Bonifacio M J ^a   Sutcliffe, J S ^b   Torrao L ^a   Wright, L C ^a   Soares Da Silva, P ^a,c  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b Singapore Science Park II   (Singapore)

^c University of Porto   (Portugal)

Author keywords

Brain microdialysis; COMT inhibition; Cynomolgus monkeys; Dorsal striatum; Levodopa pharmacokinetics; Opicapone; Prefrontal cortex; Substantia nigra

Indexed keywords

3 O METHYLDOPA; BENSERAZIDE PLUS LEVODOPA; DRUG METABOLITE; LONG ACTING DRUG; OPICAPONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORPUS STRIATUM; CROSSOVER PROCEDURE; DIALYSATE; DORSAL STRIATUM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; NONHUMAN; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBSTANTIA NIGRA;

3-METHOXY-4-HYDROXYPHENYLGLYCOL; 3-O-METHYLDOPA; 3-OMD; AADC; ACSF; AREA UNDER THE CURVE; AROMATIC AMINO ACID DECARBOXYLASE; ARTIFICIAL CEREBROSPINAL FLUID; AUC; BRAIN MICRODIALYSIS; C(MAX); CATECHOL-O-METHYLTRANSFERASE; COMT; COMT INHIBITION; CYNOMOLGUS MONKEYS; DIHYDROXYPHENYLACETIC ACID; DOPAC; DORSAL STRIATUM; EDTA; ETHYLENEDIAMINETETRAACETIC ACID; HAEMOGLOBIN; HB; HIGH PRESSURE LIQUID CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION; HOMOVANILLIC ACID; HPLC-ED; HVA; LEVODOPA PHARMACOKINETICS; MAXIMUM CONCENTRATION; METANEPHRINE; MN; MOPEG; OPICAPONE; PARKINSON'S DISEASE; PCA; PD; PERCHLORIC ACID; PREFRONTAL CORTEX; SUBSTANTIA NIGRA; T(MAX); TIME TO C(MAX);

ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CATECHOL O-METHYLTRANSFERASE; CROSS-OVER STUDIES; DOPAMINE AGENTS; DRUG INTERACTIONS; FEMALE; LEVODOPA; MACACA FASCICULARIS; MALE; OXADIAZOLES; PARKINSON DISEASE;

EID: 84887298369     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.10.014     Document Type: Article

References (35)

1. E. Acquas, E. Carboni, R.H. de Ree, M. Da Prada, and G. Di Chiara Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592 J. Neurochem. 59 1992 326 330
2. L. Almeida, J.F. Rocha, A. Falcao, P.N. Palma, A.I. Loureiro, R. Pinto, M.J. Bonifacio, L.C. Wright, T. Nunes, and P. Soares-da-Silva Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O- methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor Clin. Pharmacokinet. 52 2013 139 151
3. M.J. Bonifácio, P.N. Palma, L. Almeida, and P. Soares-da-Silva Catechol-O-methyltransferase and its inhibitors in Parkinson's disease CNS Drug Rev. 13 2007 352 379 (Pubitemid 47481088)
4. B.T. Chen, K.A. Moran, M.V. Avshalumov, and M.E. Rice Limited regulation of somatodendritic dopamine release by voltage-sensitive Ca channels contrasted with strong regulation of axonal dopamine release J. Neurochem. 96 2006 645 655
5. 2+ dependence and time course of somatodendritic dopamine release: substantia nigra versus striatum J. Neurosci. 21 2001 7841 7847 (Pubitemid 32904984)
6. J. Dingemanse, K. Jorga, G. Zürcher, B. Fotteler, G. Sedek, T. Nielsen, and P. van Brummelen Multiple-dose clinical pharmacology of the catechol-O-methyl- transferase inhibitor tolcapone in elderly subjects Eur. J. Clin. Pharmacol. 50 1996 47 55
7. D.L. Drabkin, and H. Harold Austin Spectrophotometric studies: II. Preparations from washed blood cells; nitric oxide hemoglobin and sulfhemoglobin J. Biol. Chem. 112 1935 51 65
8. G. Eisenhofer, I.J. Kopin, and D.S. Goldstein Catecholamine metabolism: a contemporary view with implications for physiology and medicine Pharmacol. Rev. 56 2004 331 349 (Pubitemid 39096594)
9. J.J. Ferreira, J.-F. Rocha, A. Falcão, R. Pinto, T. Nunes, and P. Soares-da-Silva Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics, motor response, and erythrocyte-COMT activity in Parkinson's patients co-administered with levodopa/dopa-decarboxylase inhibitor Mov. Disord. 28 S1 2013 S155
10. J.J. Ferreira, J.-F. Rocha, A. Falcão, L. Wright, T. Nunes, and P. Soares-da-Silva Effect of opicapone single-dose regimens on levodopa pharmacokinetics, motor response, and erythrocyte-COMT activity in Parkinson's patients co-administered with levodopa/dopa-decarboxylase inhibitor Neurodegener. Dis. 11 Suppl. 1 2013 PS2:P354.
11. J.J. Ferreira, J.F. Rocha, A. Santos, T. Nunes, and P. Soares-da-Silva The design of a double-blind, placebo- and active-controlled, multi-national phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: opicapone superiority vs. placebo and non-inferiority vs. entacapone Mov. Disord. 27 2012 S118
12. M. Gerlach, A.Y. Xiao, W. Kuhn, R. Lehnfeld, P. Waldmeier, K.H. Sontag, and P. Riederer The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats J. Neural Transm. 108 2001 189 204 (Pubitemid 32695761)
13. M. Huotari, R. Gainetdinov, and P.T. Mannisto Microdialysis studies on the action of tolcapone on pharmacologically- elevated extracellular dopamine levels in conscious rats Pharmacol. Toxicol. 85 1999 233 238
14. S. Kaakkola Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease Int. Rev. Neurobiol. 95 2010 207 225
15. L.E. Kiss, H.S. Ferreira, L. Torrao, M.J. Bonifacio, P.N. Palma, P. Soares-da-Silva, and D.A. Learmonth Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase J. Med. Chem. 53 2010 3396 3411
16. A. Lees, R. Costa, C. Oliveira, N. Lopes, T. Nunes, and P. Soares-da-Silva The design of a double-blind, placebo-controlled, multi-national phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: opicapone superiority vs. placebo Mov. Disord. 27 2012 S127
17. C. Marin, and J.A. Obeso Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment Int. Rev. Neurobiol. 95 2010 191 205
18. R.F. Martin, and D.M. Bowden Primate Brain Maps: Structure of the Macaque Brain 2000 Elsevier Science
19. A. Napolitano, G. Bellini, E. Borroni, G. Zurcher, and U. Bonuccelli Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats Parkinsonism Relat. Disord. 9 2003 145 150 (Pubitemid 36173563)
20. E. Nissinen, and P.T. Mannisto Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors Int. Rev. Neurobiol. 95 2010 73 118
21. M. Okada, R. Nakao, R. Hosoi, M.R. Zhang, T. Fukumura, K. Suzuki, and O. Inoue Microdialysis with radiometric monitoring of L-[beta-11C]DOPA to assess dopaminergic metabolism: effect of inhibitors of L-amino acid decarboxylase, monoamine oxidase, and catechol-O-methyltransferase on rat striatal dialysate J. Cereb. Blood Flow Metab. 31 2011 124 131
22. C.W. Olanow, and F. Stocchi COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 62 2004 S72 S81
23. P.N. Palma, M.J. Bonifacio, A.I. Loureiro, and P. Soares-da-Silva Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations J. Comput. Chem. 33 2012 970 986
24. P.N. Palma, K. Laszlo, and P. Soares-da-Silva Catechol-O- methyltransferase inhibitors: present problems and relevance of the new ones A. Martinez, C. Gil, Emerging Drugs and Targets for Parkinson's Disease 2013 The Royal Society of Chemistry Cambridge 83 109
25. A. Parada, and P. Soares-da-Silva BIA 3-202, a novel catechol-o- methyltransferase inhibitor, reduces the peripheral o-methylation of L-DOPA and enhances its availability to the brain Pharmacology 68 2003 29 37 (Pubitemid 36356928)
26. P.E. Phillips, P.J. Hancock, and J.A. Stamford Time window of autoreceptor-mediated inhibition of limbic and striatal dopamine release Synapse 44 2002 15 22 (Pubitemid 34174374)
27. J.-F. Rocha, A. Falcao, R. Pinto, T. Nunes, and P. Soares-da-Silva Effect of opicapone and entacapone on levodopa pharmacokinetics when administered with immediate release 100/25 mg levodopa/carbidopa in healthy subjects Mov. Disord. 28 Suppl. 1 2013 S-155-S155
28. J.F. Rocha, L. Almeida, A. Falcao, P.N. Palma, A.I. Loureiro, R. Pinto, M.J. Bonifacio, L.C. Wright, T. Nunes, and P. Soares-da-Silva Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple-dose administration in healthy subjects Br. J. Clin. Pharmacol. 76, Jan 21 2013 763 775 10.1111/bcp.12081
29. M.C. Rodriguez-Oroz, C. Marin, and O. de Fabregues Continuous dopaminergic stimulation: clinical aspects and experimental bases Neurologist 17 2011 S30 S37
30. J. Rouru, A. Gordin, R. Huupponen, S. Huhtala, E. Savontaus, K. Korpela, K. Reinikainen, and M. Scheinin Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition Eur. J. Clin. Pharmacol. 55 1999 461 467 (Pubitemid 29399659)
31. S. Saiki, S. Sato, and N. Hattori Molecular pathogenesis of Parkinson's disease: update J. Neurol. Neurosurg. Psychiatry 83 2012 430 436
32. A.H. Schapira, and P. Jenner Etiology and pathogenesis of Parkinson's disease Mov. Disord. 26 2011 1049 1055
33. J.M. Shulman, P.L. De Jager, and M.B. Feany Parkinson's disease: genetics and pathogenesis Annu. Rev. Pathol. 6 2011 193 222
34. M.A. Vieira-Coelho, and P. Soares-da-Silva Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase Brain Res. 821 1999 69 78 (Pubitemid 29219681)
35. L. Yavich, M.M. Forsberg, M. Karayiorgou, J.A. Gogos, and P.T. Mannisto Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum J. Neurosci. 27 2007 10196 10209